Risofos 35 mg Tablet

Side Effects of Risofos 35 mg Tablet

Electrolyte disturbances; GI disturbances; musculoskeletal pain; headache; hypersensitivity reactions; blood disorders; liver enzyme disturbances. Bone, joint and/or muscle pain.

Drug Interactions

Co-admin with calcium, antacids or oral medications containing divalent cations may affect the absorption of risedronate. May have additive calcium lowering effects when used with aminoglycosides.

Contraindications

Acute upper GI inflammation, pregnancy, hypocalcaemia and CrCl <30 ml/min.

Mechanism of Action

Risedronic acid inhibits bone resorption by inhibiting osteoclasts. It also prevents formation and dissolution of hydroxyapatite crystals, and therefore may interfere with bone mineralisation. Absorption: Poor absorption after oral admin. Distribution: Protein binding: about 24%. Metabolism: Not metabolised. Excretion: About half of the absorbed portion is excreted in the urine within 24 hr. Unabsorbed drug is eliminated in the faeces.

Special Precautions

Correct hypocalcaemia prior to therapy. Monitor hepatic and renal function and WBC. Renal impairment; inability to remain in an upright position for at least 30 min after oral intake.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.